CoChat

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

The human-specific paralogs SRGAP2B and SRGAP2C differentially modulate SRGAP2A-dependent synaptic development

Open access

Published version of a preprint

Abstract

Human-specific gene duplications (HSGDs) have recently emerged as key modifiers of brain development and evolution. However, the molecular mechanisms underlying the function of HSGDs remain often poorly understood. In humans, a truncated duplication of SRGAP2A led to the emergence of two human-specific paralogs: SRGAP2B and SRGAP2C. The ancestral copy SRGAP2A limits synaptic density and promotes maturation of both excitatory (E) and inhibitory (I) synapses received by cortical pyramidal neurons (PNs). SRGAP2C binds to and inhibits all known functions of SRGAP2A leading to an increase in E and I synapse density and protracted synapse maturation, traits characterizing human cortical neurons. Here, we demonstrate how the evolutionary changes that led to the emergence of SRGAP2 HSGDs generated proteins that, in neurons, are intrinsically unstable and, upon hetero-dimerization with SRGAP2A, reduce SRGAP2A levels in a proteasome-dependent manner. Moreover, we show that, despite only a few non-synonymous mutations specifically targeting arginine residues, SRGAP2C is unique compared to SRGAP2B in its ability to induce long-lasting changes in synaptic density throughout adulthood. These mutations led to the ability of SRGAP2C to inhibit SRGAP2A function and thereby contribute to the emergence of human-specific features of synaptic development during evolution.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-019-54887-4

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 SRGAP2A and the emergence of the human-specific paralogs SRGAP2B and SRGAP2C. (A) The ancestral copy SRGAP2A, present in rodents, primates, and humans, was duplicated in the human lineage to form the truncated copies SRGAP2B and SRGAP2C. (B) SRGAP2A contains three distinct protein domains. Through binding of Homer1 to an EVH1 site in the F-BAR domain, SRGAP2A promotes maturation of excitatory synapses, while binding of Gephyrin to the SH3 domain promotes inhibitory synapse maturation. The Rho-GAP domain is involved in limiting synapse density through Rac1. (C) Duplication of SRGAP2A in humans generated a truncated protein, F-BARΔ49, containing the F-BARx domain of SRGAP2A that lacks the last C-terminal 49 amino acids. Subsequent nonsynonymous base pair mutations converted arginines to non-polar residues which led to the formation of SRGAP2B and SRGAP2C. Binding of SRGAP2C to SRGAP2A inhibits all functions of SRGAP2A. (D) In rodents, synaptic development of cortical pyramidal neurons is complete at P21. At this stage, both synapse size and synaptic density reach levels of those observed in adulthood. In contrast, expression of SRGAP2C in mouse cortical pyramidal neurons binds and inhibits SRGAP2A resulting in protracted synaptic maturation and increased synaptic density.
Figure 1 SRGAP2A and the emergence of the human-specific paralogs SRGAP2B and SRGAP2C. (A) The ancestral copy SRGAP2A, present in rodents, primates, and humans, was duplicated in the human lineage to form the truncated copies SRGAP2B and SRGAP2C. (B) SRGAP2A contains three distinct protein domains. Through binding of Homer1 to an EVH1 site in the F-BAR domain, SRGAP2A promotes maturation of excitatory synapses, while binding of Gephyrin to the SH3 domain promotes inhibitory synapse maturation. The Rho-GAP domain is involved in limiting synapse density through Rac1. (C) Duplication of SRGAP2A in humans generated a truncated protein, F-BARΔ49, containing the F-BARx domain of SRGAP2A that lacks the last C-terminal 49 amino acids. Subsequent nonsynonymous base pair mutations converted arginines to non-polar residues which led to the formation of SRGAP2B and SRGAP2C. Binding of SRGAP2C to SRGAP2A inhibits all functions of SRGAP2A. (D) In rodents, synaptic development of cortical pyramidal neurons is complete at P21. At this stage, both synapse size and synaptic density reach levels of those observed in adulthood. In contrast, expression of SRGAP2C in mouse cortical pyramidal neurons binds and inhibits SRGAP2A resulting in protracted synaptic maturation and increased synaptic density.CC BY · PubMed Central
Figure 2 Proteasome degradation of SRGAP2 proteins. (A) Expression of RFP-tagged F-BARx, F-BARΔ49, or SRGAP2C in mouse cortical pyramidal neurons cultured for 18–21 days in vitro (DIV). Low levels of expression were observed for F-BARΔ49 and SRGAP2C, while addition of the proteasome inhibitor MG-132 resulted in a strong increase after 8 h of treatment. F-BARx is highly expressed throughout the experiment. Scale bar top panels: 25 µm, bottom panels: 5 µm. (B) Quantification of fluorescence intensity after MG-132 treatment. nF-BARx = 31 neurons, nF-BARΔ49 = 50 neurons, nSRGAP2C = 47 neurons; multiple t tests with Holm-Sidak correction for multiple comparisons (α = 0.05); ****p < 0.0001; mean ± SEM. (C–E) Co-expression of SRGAP2A and SRGAP2C in cultured mouse cortical neurons. SRGAP2A levels are reduced when co-expressed with SRGAP2C in both soma and dendritic spines. Scale bars: 5 µm. (E) Quantification of SRGAP2A fluorescence intensity. Soma: nControl = 110, nSRGAP2C = 68; Spines: nControl = 969, nSRGAP2C = 1259; Mann-Whitney test; ***p < 0.001; mean ± SEM. (F) Treatment of cultured mouse cortical neurons expressing both SRGAP2A-GFP and SRGAP2C-RFP with MG-132. Levels for both SRGAP2A and SRGAP2C increased upon treatment, and co-localization of SRGAP2A and SRGAP2C protein clusters were observed (red arrow). Scale bar: 10 µm. (G) Quantification of SRGAP2A fluorescent intensity when co-expressed with either F-BARx or SRGAP2C in the presence of MG-132. nF-BAR = 60 neurons, nSRGAP2C = 59 neurons; multiple t tests with Holm-Sidak correction for multiple comparisons (α = 0.05); ***p < 0.001; mean ± SEM.
Figure 2 Proteasome degradation of SRGAP2 proteins. (A) Expression of RFP-tagged F-BARx, F-BARΔ49, or SRGAP2C in mouse cortical pyramidal neurons cultured for 18–21 days in vitro (DIV). Low levels of expression were observed for F-BARΔ49 and SRGAP2C, while addition of the proteasome inhibitor MG-132 resulted in a strong increase after 8 h of treatment. F-BARx is highly expressed throughout the experiment. Scale bar top panels: 25 µm, bottom panels: 5 µm. (B) Quantification of fluorescence intensity after MG-132 treatment. nF-BARx = 31 neurons, nF-BARΔ49 = 50 neurons, nSRGAP2C = 47 neurons; multiple t tests with Holm-Sidak correction for multiple comparisons (α = 0.05); ****p < 0.0001; mean ± SEM. (C–E) Co-expression of SRGAP2A and SRGAP2C in cultured mouse cortical neurons. SRGAP2A levels are reduced when co-expressed with SRGAP2C in both soma and dendritic spines. Scale bars: 5 µm. (E) Quantification of SRGAP2A fluorescence intensity. Soma: nControl = 110, nSRGAP2C = 68; Spines: nControl = 969, nSRGAP2C = 1259; Mann-Whitney test; ***p < 0.001; mean ± SEM. (F) Treatment of cultured mouse cortical neurons expressing both SRGAP2A-GFP and SRGAP2C-RFP with MG-132. Levels for both SRGAP2A and SRGAP2C increased upon treatment, and co-localization of SRGAP2A and SRGAP2C protein clusters were observed (red arrow). Scale bar: 10 µm. (G) Quantification of SRGAP2A fluorescent intensity when co-expressed with either F-BARx or SRGAP2C in the presence of MG-132. nF-BAR = 60 neurons, nSRGAP2C = 59 neurons; multiple t tests with Holm-Sidak correction for multiple comparisons (α = 0.05); ***p < 0.001; mean ± SEM.CC BY · PubMed Central
Figure 3 In vivo analysis of spine density and spine size at juvenile stage. (A) Schematic illustrating in utero electroporation approach targeting layer 2/3 cortical pyramidal neurons and subsequent quantification of dendritic spine density and head size. Scale bar: 50 µm. (B) Representative images showing apical oblique dendrites of neurons at P21 co-expressing either Venus and tdTomato (Control), or mRFP-tagged F-BARx, F-BARΔ49, SRGAP2B, or SRGAP2C. Scale bar: 2 µm. (C,D) Quantification of spine density (C) and spine head size (D). Quantifications are shown as frequency distributions. Spine density (segments): nControl = 26, nF-BARx = 25, nF-BARΔ49 = 34, nSRGAP2B = 25, nSRGAP2C = 25; Spine size (number of spines): nControl = 1693, nF-BARx = 2054, nF-BARΔ49 = 3267, nSRGAP2B = 2900, nSRGAP2C = 2448; one-way ANOVA with Holm-Sidak’s post hoc multiple comparison test; *p < 0.05, ****p < 0.0001 compared to control.
Figure 3 In vivo analysis of spine density and spine size at juvenile stage. (A) Schematic illustrating in utero electroporation approach targeting layer 2/3 cortical pyramidal neurons and subsequent quantification of dendritic spine density and head size. Scale bar: 50 µm. (B) Representative images showing apical oblique dendrites of neurons at P21 co-expressing either Venus and tdTomato (Control), or mRFP-tagged F-BARx, F-BARΔ49, SRGAP2B, or SRGAP2C. Scale bar: 2 µm. (C,D) Quantification of spine density (C) and spine head size (D). Quantifications are shown as frequency distributions. Spine density (segments): nControl = 26, nF-BARx = 25, nF-BARΔ49 = 34, nSRGAP2B = 25, nSRGAP2C = 25; Spine size (number of spines): nControl = 1693, nF-BARx = 2054, nF-BARΔ49 = 3267, nSRGAP2B = 2900, nSRGAP2C = 2448; one-way ANOVA with Holm-Sidak’s post hoc multiple comparison test; *p < 0.05, ****p < 0.0001 compared to control.CC BY · PubMed Central
Figure 4 In vivo analysis of spine density and spine size at the adult stage. (A) Representative images showing apical oblique dendrites of adult neurons co-expressing either Venus (shown) and tdTomato (Control), or mRFP-tagged F-BARx, F-BARΔ49, SRGAP2B, or SRGAP2C (not shown). Scale bar: 2 µm. (B,C) Quantification of spine density (B) and spine head size (C). Quantifications are shown as frequency distributions. Spine density (segments): nControl = 25, nF-BARx = 24, nF-BARΔ49 = 22, nSRGAP2B = 27, nSRGAP2C = 25; Spine size (number of spines): nControl = 1872, nF-BARx = 2049, nF-BARΔ49 = 1843, nSRGAP2B = 2295, nSRGAP2C = 2630; one-way ANOVA with Holm-Sidak’s post hoc multiple comparison test; NS: p > 0.05, *p < 0.05, ***p < 0.001, ****p < 0.0001 compared to control.
Figure 4 In vivo analysis of spine density and spine size at the adult stage. (A) Representative images showing apical oblique dendrites of adult neurons co-expressing either Venus (shown) and tdTomato (Control), or mRFP-tagged F-BARx, F-BARΔ49, SRGAP2B, or SRGAP2C (not shown). Scale bar: 2 µm. (B,C) Quantification of spine density (B) and spine head size (C). Quantifications are shown as frequency distributions. Spine density (segments): nControl = 25, nF-BARx = 24, nF-BARΔ49 = 22, nSRGAP2B = 27, nSRGAP2C = 25; Spine size (number of spines): nControl = 1872, nF-BARx = 2049, nF-BARΔ49 = 1843, nSRGAP2B = 2295, nSRGAP2C = 2630; one-way ANOVA with Holm-Sidak’s post hoc multiple comparison test; NS: p > 0.05, *p < 0.05, ***p < 0.001, ****p < 0.0001 compared to control.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 55

Metadata

Authors
Schmidt, E. R. E., Kupferman, J. V., Stackmann, M., & Polleux, F.
Affiliations
Mortimer B. Zuckerman Mind Brain Behavior Institute (US)
Corresponding author
Polleux, Franck
Venue
Scientific Reports
Published
2019-12-10
Volume
9
Issue
1
Pages
18692-18692
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2995487222
Cited by
55
References
28
Citations by year
2026: 6 · 2025: 7 · 2024: 14 · 2023: 13 · 2022: 5 · 2021: 8 · 2020: 2
FWCI
2.26
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS067557)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Neuroscience › Developmental Neuroscience › Neurogenesis and neuroplasticity mechanisms
Keywords
synaptic development, synaptic density, synapse maturation, excitatory and inhibitory synapses, cortical pyramidal neurons, protein instability, proteasomal degradation, heterodimerization, non-synonymous mutations, human brain evolution, brain development
MeSH terms
Animals, Humans, Neurons, Synapses, Pyramidal Cells, Evolution, Molecular, Gene Duplication, GTPase-Activating Proteins, Organogenesis, Cell Line, Tumor, Mice, Primary Cell Culture

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The human-specific paralogs SRGAP2B and SRGAP2C differentially modulate SRGAP2A-dependent synaptic development. https://app.cochat.ai/papers/10.1038/s41598-019-54887-4
The paper
Schmidt, E. R. E., Kupferman, J. V., Stackmann, M., & Polleux, F. (2019). The human-specific paralogs SRGAP2B and SRGAP2C differentially modulate SRGAP2A-dependent synaptic development. Scientific Reports. https://doi.org/10.1038/s41598-019-54887-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.